OTC Obesity - Norway

June 2010 | 39 pages | ID: OA28CD75AF2EN
Euromonitor International Ltd

Abstracts

Sales of OTC obesity products reached NOK10 million in 2009 following the introduction of the first clinically-approved product in this category.

Euromonitor International's OTC Obesity Products in Norway report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Consumer Health industry;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

Executive Summary
Consumer Healthcare Characterised by Simple and Preventative Remedies
Krill Oil - A New Generation of Omega-3 Products
Many Players With Small Value Share
Chemists/pharmacies Leads Distribution Value Sales
Moderate Growth Predicted During Forecast Period
Key Trends and Developments
Emergence of Mass Brands Puts Downward Pressure on Prices
Swine Flu Hits Norway
Chemists/pharmacies Has Loyal and Satisfied Customers
More Advertising of Consumer Healthcare on Television
Increased Online Shopping for Consumer Healthcare Products
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 3 Life Expectancy at Birth 2004-2009
Market Data
  Table 4 Sales of Consumer Health by Sector: Value 2004-2009
  Table 5 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 6 Consumer Health Company Shares by Value 2005-2009
  Table 7 Consumer Health Brand Shares by Value 2006-2009
  Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
De-listing Or De-reimbursement
Bioequivalents/generics
Advertising
Packaging
Labelling
Distribution
New Pharmacy Act of 2001 Enabled New Players To Enter Norway
Nrt Smoking Cessation Aids Available for Sale in Non-pharmacy Outlets Since 2003
Further Deregulation - Consumer Healthcare Products Finally Sold Through Grocery Retailers
Vitamins and Dietary Supplements Registration and Classification
National Legislation and Regulation
Advertising
Distribution
Grocery Retailers Important in Sale of Vitamins and Dietary Supplements
Direct Selling Only Applies To Vitamins and Dietary Supplements
Self-medication/self-care and Preventative Medicine
Switches
  Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
  Summary 2 Research Sources
Actavis Nordic A/S
Strategic Direction
Key Facts
  Summary 3 Actavis Nordic A/S: Key Facts
  Table 12 Actavis Nordic A/S: Operational Indicators
Company Background
Production
  Summary 4 Actavis Nordic A/S: Production Statistics 2009
Competitive Positioning
  Summary 5 Actavis Nordic A/S: Competitive Position 2009
Brynild Gruppen As
Strategic Direction
Key Facts
  Summary 6 Brynild Gruppen AS: Key Facts
  Summary 7 Brynild Gruppen AS: Operational Indicators
Company Background
Competitive Positioning
  Summary 8 Brynild Gruppen AS : Competitive Position 2008
Midelfart Sonesson As
Strategic Direction
Key Facts
  Summary 9 Midelfart Sonesson AS: Key Facts
  Table 13 Midelfart Sonesson AS: Operational Indicators
Company Background
Competitive Positioning
  Summary 10 Midelfart Sonesson AS: Competitive Position 2008
Nycomed Pharma As
Strategic Direction
Key Facts
  Summary 11 Nycomed Pharma AS: Key Facts
  Table 14 Nycomed Pharma AS: Operational Indicators
Company Background
Production
  Summary 12 Nycomed Pharma AS: Production Statistics 2007
Competitive Positioning
  Summary 13 Nycomed Pharma AS: Competitive Position 2008
Weifa As
Strategic Direction
Key Facts
  Summary 14 Weifa AS: Key Facts
  Table 15 Weifa AS: Operational Indicators
Company Background
Production
  Summary 15 Weifa AS: Production Statistics 2007
Competitive Positioning
  Summary 16 Weifa AS: Competitive Position 2008
Trends
Category Data
  Table 16 Sales of OTC Obesity: Value 2009
  Table 17 OTC Obesity Company Shares by Value 2005-2009
  Table 18 OTC Obesity Brand Shares by Value 2006-2009
  Table 19 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 20 Forecast Sales of OTC Obesity: % Value Growth 2009-2014